Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Pablo Barreiro, Fernando de Jesus, Octavio Corral & Carmen de Mendoza. (2023) Safety considerations in the management of hepatitis C and HIV co-infection. Expert Opinion on Drug Safety 22:5, pages 363-372.
Read now
Read now
Hossam Abdelaziz, Heba Omar, Mahmoud Khalil, Ahmed Cordie, Rahma Mohamed, Mohamed AbdAllah, Mohammed Hamdy Abdel Maksoud, Naeema El Garhy, Lamiaa Ali, Magdy El Serafy, Gamal Esmat & Wahid Doss. (2022) Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Review of Anti-infective Therapy 20:5, pages 789-795.
Read now
Read now
Lu-Hua Gao, Qing-He Nie & Xi-Tai Zhao. (2021) Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. International Journal of General Medicine 14, pages 289-301.
Read now
Read now
Articles from other publishers (12)
Raquel Boff da Costa, Marisa Boff Costa, Larisse Longo, Daniela Elisa Miotto, Gustavo Hirata Dellavia, Matheus Trucollo Michalczuk & Mario Reis Álvares-da-Silva. (2021) Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications. PLOS ONE 16:2, pages e0245767.
Crossref
Crossref
CARINA S. LIBRELOTTO, ANA PAULA DE SOUZA, MÁRIO R. ÁLVARES-DA-SILVA, DANIEL SIMON & RAFAEL R. DIHL. (2021) Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line. Anais da Academia Brasileira de Ciências 93:4.
Crossref
Crossref
Nadège Néant & Caroline Solas. (2020) Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection. International Journal of Antimicrobial Agents 56:1, pages 105571.
Crossref
Crossref
Eleanor Wilson, Emily Covert, Jennifer Hoffmann, Emily Comstock, Benjamin Emmanuel, Lydia Tang, Jennifer Husson, Joel Chua, Angie Price, Poonam Mathur, Elana Rosenthal, Sarah Kattakuzhy, Henry Masur & Shyam Kottilil. (2019) A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). Journal of Hepatology 71:3, pages 498-504.
Crossref
Crossref
Hong Xiao, Jun Chen, Jiangrong Wang, Juhua Li, Feia Yang & Hongzhou Lu. (2019) Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. Medicine 98:30, pages e16524.
Crossref
Crossref
Gema Lledó, Laura Benítez-Gutiérrez, Ana Arias, Silvia Requena, Valentín Cuervas-Mons & Carmen de Mendoza. (2019) Benefits of hepatitis C cure with antivirals: why test and treat?. Future Microbiology 14:5, pages 425-435.
Crossref
Crossref
Dominique Salmon-Ceron, J. E. Arends, C. Leoni, C. Solas & G. Peytavin. 2019. Viral Hepatitis: Chronic Hepatitis C. Viral Hepatitis: Chronic Hepatitis C
141
157
.
Ashish Dogra, Shipra Bhatt, Asmita Magotra, Anjna Sharma, Pankul Kotwal, Abhishek Gour, Priya Wazir, Gurdarshan Singh & Utpal Nandi. (2018) Intervention of curcumin on oral pharmacokinetics of daclatasvir in rat: A possible risk for long-term use. Phytotherapy Research 32:10, pages 1967-1974.
Crossref
Crossref
J. von Felden, J. Vermehren, P. Ingiliz, S. Mauss, T. Lutz, K. G. Simon, H. W. Busch, A. Baumgarten, K. Schewe, D. Hueppe, C. Boesecke, J. K. Rockstroh, M. Daeumer, N. Luebke, J. Timm, J. Schulze zur Wiesch, C. Sarrazin & S. Christensen. (2018) High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Alimentary Pharmacology & Therapeutics 47:9, pages 1288-1295.
Crossref
Crossref
J Bischoff, S Mauss, C Cordes, T Lutz, S Scholten, A Moll, H Jäger, M Cornberg, MP Manns, A Baumgarten & JK Rockstroh. (2018) Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?. HIV Medicine 19:4, pages 299-307.
Crossref
Crossref
Alessio Aghemo, Lionel Piroth & Sanjay Bhagani. (2018) What do clinicians need to watch for with direct-acting antiviral therapy?. Journal of the International AIDS Society 21, pages e25076.
Crossref
Crossref
Vasily Isakov, Natalia Gankina, Viacheslav Morozov, Kathryn Kersey, Sophia Lu, Anu Osinusi, Evguenia Svarovskaia, Diana M. Brainard, Riina Salupere, Elena Orlova-Morozova & Konstantin Zhdanov. (2017) Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection. Clinical Drug Investigation 38:3, pages 239-247.
Crossref
Crossref